Advertisement

Topics

Latest Biotechnology, Pharmaceutical and Healthcare News from Globe Newswire

14:58 EST 21st November 2018 | BioPortfolio

Here are the most relevant search results for "Globe Newswire" found in our extensive news archives from over 250 global news sources.

More Information about Globe Newswire on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Globe Newswire for you to read. Along with our medical data and news we also list Globe Newswire Clinical Trials, which are updated daily. BioPortfolio also has a large database of Globe Newswire Companies for you to search.

Showing News Articles 1–25 of 22,000+ from Globe Newswire

Tuesday 20th November 2018

International Cannabis Corp. Building Global Network -- CFN Media

SEATTLE, Nov. 21, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article covering International Cannabis Corp. (CSE: WRLD, OTC: KNHBF), also known as ICC, a vertically-integrated cannabis company specializing in the acquisition and ope...

Supreme Cannabis Focused on Disciplined Deployment of Capital -- CFN Media

SEATTLE, Nov. 21, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing Supreme Cannabis Co. (TSX-V: FIRE) (OTCQX: SPRWF). The cannabis industry has boomed in recent years supported by the access to inexpensive capital, wh...

Halo Labs: Improving Investor Reach, Transparency, and Liquidity -- CFN Media

SEATTLE, Wash., Nov. 21, 2018 (GLOBE NEWSWIRE) -- -- via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing Halo Labs Inc. (NEO: HALO) (OTC: AGEEF). HALO is a cannabis extraction company that develops and manufactures high-quality cannabis oils and c...

BLOCKStrain Brings Security, Scalability, and Transparency to Cannabis Supply Chain, Plus Exclusive Executive Interview -- CFN Media

SEATTLE, Nov. 21, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article and video interview discussing BLOCKStrain Technology Corp. (TSXV: DNAX) (OTC Pink: BKKSF). Chief Technology Officer Tommy Stephenson recently sat down with CFN M...

VBL Therapeutics to Present at the Piper Jaffray 30th Annual Healthcare Conference on November 28

TEL AVIV, Israel, Nov. 21, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announces it will provide a corporate update, in a Fireside Chat format, at the Piper Jaffray 30th Annual Healthcare Conference, to be held at the Lotte New York Pala...

BioSyent Releases Results for Third Quarter and First Nine Months of 2018

TORONTO, Nov. 21, 2018 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today a summary of its financial results for the three and nine months ended September 30, 2018. Key highlights include: Third quarter (Q3) 2018 Net Revenues of $5,259,493 decreased by 3% versus Q3 2017First nine months (YTD) 2018 Net Revenues of $15,616,063 increased by 5% versus Y...

PhaseBio To Report Third Quarter 2018 Financial and Business Results on November 29, 2018

MALVERN, Pa. and SAN DIEGO, Nov. 21, 2018 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for orphan diseases, with an initial focus on cardiopulmonary disorders, today announced it will report financial and business results for the third quarter of 2018 on November ...

Abattis Retains Canadian and American Compliance Agency and Provides Company Update

VANCOUVER, British Columbia, Nov. 21, 2018 (GLOBE NEWSWIRE) -- Abattis Bioceuticals Corp (the “Company” or “Abattis”) (CSE:ATT) (OTC:ATTBF) is pleased to announce the appointment of Ingredient Identity LLC (“Ingredient Identity”), a Canadian and US regulatory and compliance agency, to assist the Company’s wholly-owned subsidiary, Vergence Naturals Ltd. (“Vergence Naturals”), w...

CureVac to Present at the 19th Annual Piper Jaffray Healthcare Conference

TÜBINGEN, Germany and BOSTON, Nov. 21, 2018 (GLOBE NEWSWIRE) -- CureVac AG, a fully integrated biopharmaceutical company pioneering the field of mRNA-based drugs, today announced that Dan Menichella, Chief Executive Officer, will present a corporate overview at the 19th Annual Piper Jaffray Healthcare Conference in New York on Tuesday, November 27, 2018 at 10:50 a.m. ET. A live audio broadca...

Aleafia and Serruya Private Equity Reach Agreement for National Retail Dispensary, top Performing Brands and $10M Investment

Transactions Positions Aleafia as Major Supplier, Retailer of Adult-use Cannabis TORONTO, Nov. 21, 2018 (GLOBE NEWSWIRE) -- Aleafia Health Inc. (TSXV: ALEF; OTCQX: ALEAF, FRA: ARAH) (“Aleafia“ or the “Company“), and Serruya Private Equity (“Serruya” and together with the Company, the “Parties”), have settled final forms of definitive joint venture and other agreements that wil...

Clementia to Present at the Evercore ISI HealthCONx Conference

MONTREAL, Nov. 21, 2018 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (Nasdaq: CMTA), a clinical-stage biopharmaceutical company innovating treatments for people with ultra-rare bone disorders and other diseases, today announced that Clarissa Desjardins, Ph.D., chief executive officer and founder of Clementia, will present at the Evercore ISI HealthCONx Conference on Wednesday, November 28...

The Phase III study protocol is modified after IBT’s meeting with the FDA

The Phase III study protocol is modified after IBT’s meeting with the FDA Yesterday afternoon (EST) Infant Bacterial Therapeutics had a meeting with the US Food and Drug Administration (FDA) in Washington DC to discuss the design of the company's clinical development program. As a consequence of these discussions, IBT has chosen to modify its Phase III study for the prevention of necrotizing ...

Monday 19th November 2018

Tyme Technologies, Inc. to Present at the Evercore ISI, HealthconX Conference on November 27th

NEW YORK, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME), a clinical stage biotechnology company developing cancer therapeutics to address multiple tumor types, today announced that it will be featured as a presenting company at the Evercore ISI, HealthconX Conference.  The conference is being held on November 27 -29, 2018 at the Boston Harbor Hotel in Boston, MA. Dr...

Nabriva Therapeutics to Present at the 30th Annual Piper Jaffray Healthcare Conference

DUBLIN, Ireland and KING OF PRUSSIA, Pa., Nov. 20, 2018 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Officer, will provide a company overview and business update at the 30th Annual Piper ...

Amphastar Pharmaceuticals to Present at the 30th Annual Piper Jaffray Healthcare Conference 2018

RANCHO CUCAMONGA, Calif., Nov. 20, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, CFO will be presenting at the 30th Annual Piper Jaffray Healthcare Conference on Wednesday, November 28, 2018 at 1:30 p.m. Eastern Time, New York, NY. This presentation will be made available with a live webcast and may be accessed by visiting Amphastar...

Novelion Therapeutics Announces Leadership Change

Novelion General Counsel Benjamin Harshbarger Appointed as Interim Chief Executive Officer (CEO) VANCOUVER, British Columbia, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), today announced that General Counsel, Benjamin Harshbarger, has been appointed as interim CEO, reporting to Novelion’s Executive Chair, Mark Corrigan, M.D., effective immediately. Jeffrey ...

electroCore, Inc. to Present at the Evercore ISI HealthCONx Conference

BASKING RIDGE, N.J., Nov. 20, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc. (“electroCore”) (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the company will be participating in the upcoming Evercore ISI HealthCONx Conference in Boston, MA. electroCore’s management is scheduled to present on Tuesday, November 27, 2018 at 2:20 PM Eastern Time.  Interested...

Xtraction Services -- Revolutionary Technology, Service & Business Model -- CFN Media

Seattle, WA, Nov. 20, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article covering Florida-based Xtraction Services (XS). The company was formed in 2017 as a turnkey extraction solutions company with three main focuses; the supply of...

Elite Pharmaceuticals Receives FDA Approval for Hydrocodone and Acetaminophen Combo

NORTHVALE, N.J., Nov. 20, 2018 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB: ELTP), a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, today announced that it received approval from the U.S. Food and Drug Administration (FDA) for the Company’s abbreviated new drug application (ANDA) for a generic version of ...

Shire plc: Phase I conditional clearance by the European Commission

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION FOR IMMEDIATE RELEASE NOVEMBER 20, 2018 RECOMMENDED OFFER for SHIRE PLC by TAKEDA PHARMACEUTICAL COMPANY LIMITED Phase I conditi

Auris Medical Announces Results of Pre-IND Meeting With FDA For AM-201 Program in Olanzapine-Induced Weight Gain

Zug, Switzerland, November 20, 2018 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and mental health supportive care, today announced the results of its pre-Investigational New Drug (pre-IND) meeting with the United States Food & Drug Administration (FDA), where the FDA addresse...

Aptevo Therapeutics to Present at the 30th Annual Piper Jaffray Healthcare Conference

SEATTLE, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced that management will be presenting at the 30th Annual Piper Jaffray Healthcare Conference on Tuesday, November 27th, 2018 at 3:00 p.m. EST at the Lotte New York Palace Hotel in New York, NY. A live audio w...

Pure Global Poised to Advance Its Innovative Products to Distribution Channels -- CFN Media

SEATTLE, Nov. 20, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article covering Pure Global Cannabis Inc. (TSX.V:PURE; OTC: PRCNF; FRA:1QS). Pure Global is a growth-oriented life sciences cannabis company which plans to serve the mark...

Alzamend Neuro™ Appoints New CEO, Bio-Pharma Executive Stephan Jackman

Salt Lake City, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Alzamend Neuro™, Inc. (Alzamend™ or the “Company”) announced today that it has appointed bio-pharma executive, Mr. Stephan Jackman, as its new Chief Executive Officer in fulfillment of its goal to attract and secure a full-time proven industry leader to move the Company to the next level. Mr. Jackman has over twenty years of multi-indust...

Data from Phase III MAIA Study of Daratumumab Accepted for Presentation at Annual Meeting of American Society of Hematology

Media Release Data from Phase III MAIA study in front line multiple myeloma accepted as Late-breaking Abstract for oral presentation at ASH Annual Meeting Copenhagen, Denmark; November 20, 2018 – Genmab A/S (Nasdaq Copenhagen: GEN) announced today that data from the Phase III MAIA study of daratumumab in front line multiple myeloma, which was submitted by our collaboration partner Janssen...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks